RNAs offer similar advantages as the whole tumor cell lysate; this form of therapy has no HLA-restriction, multiple tumor-associated antigens can be targeted at the same time, and both CD4+ and CD8+ T cell responses can be elicited via DCs. Here, CD8A is linked to neoplasm.